RADNOR,
Pa., Sept. 26, 2023 /PRNewswire/ -- Avantor,
Inc. (NYSE: AVTR), a leading global provider of mission-critical
products and services to customers in the life sciences and
technology industries, today announced that Benoit Gourdier will join the company as EVP,
Biopharma Production on October 2,
2023. Mr. Gourdier will succeed Dr. Ger Brophy, who will retire from the company on
February 29, 2024. Following his
retirement, Dr. Brophy will continue to serve as an advisor to the
company as well as Chair of the Avantor Scientific Advisory
Board.
Mr. Gourdier joins Avantor with more than 25 years in the life
sciences industry, with a track record of driving growth and
leading global commercial organizations. He joins the company from
Millipore Sigma, where he most recently served as Senior Vice
President and General Manager, BioReliance® Contract
Testing Services. Previously, he was Vice President and Head of
Bioprocessing within Merck KGaA, Darmstadt, Germany, and held accountability for the
Asia Pacific region. Benoit
started his career at Millipore where he held various roles in
field marketing and sales. He attended Polytech Clermont in
France where he earned a master's
degree in biotechnology engineering.
"Benoit has a terrific combination of bioprocessing expertise,
commercial leadership and business acumen, and a global growth
mindset. His appointment reflects our commitment to building a
leading bioprocessing platform and a strong Executive Leadership
Team," said Michael Stubblefield,
President and CEO, Avantor. "I am confident that Benoit will be a
major contributor to Avantor's next chapter of growth."
Added Stubblefield, "Ger has been instrumental to building our
bioproduction capabilities, scaling our global manufacturing and
R&D, and deepening customer relationships. He and Benoit will
work closely together over the next five months to ensure a smooth
transition, and Ger will continue to provide value as an advisor
following his retirement."
Dr. Brophy joined Avantor in 2018. His contributions include
expanding Avantor's bioproduction capabilities and geographic
footprint, leading development of products and solutions to support
new biologic platforms and establishing innovation centers to
facilitate customer collaboration around the world.
About Avantor
Avantor®, a Fortune 500
company, is a leading global provider of mission-critical products
and services to customers in the life sciences and technology
industries. Our portfolio is used in virtually every stage of the
most important research, development and production activities in
the industries we serve. Our global footprint enables us to serve
more than 300,000 customer locations and gives us extensive access
to research laboratories and scientists in more than 180 countries.
We set science in motion to create a better world. For more
information, visit avantorsciences.com and find us on LinkedIn,
Twitter and Facebook.
Forward-Looking and Cautionary Statements
This press
release contains forward-looking statements. All statements other
than statements of historical fact included in this press release
are forward-looking statements. Forward-looking statements discuss
our current expectations and projections relating to our financial
condition, results of operations, plans, objectives, future
performance and business.
Forward-looking statements are inherently subject to risks,
uncertainties and assumptions; they are not guarantees of
performance. You should not place undue reliance on these
statements. We have based these forward-looking statements on our
current expectations and projections about future events. Although
we believe that our assumptions made in connection with the
forward-looking statements are reasonable, we cannot assure you
that the assumptions and expectations will prove to be correct.
Factors that could contribute to these risks, uncertainties and
assumptions include, but are not limited to, the factors described
in "Risk Factors" in our most recent Annual Report on
Form 10-K and quarterly reports on
Form 10-Q, as such risk factors may be updated from time
to time in our periodic filings with the SEC.
All forward-looking statements attributable to us or persons
acting on our behalf are expressly qualified in their entirety by
the foregoing cautionary statements. In addition, all
forward-looking statements speak only as of the date of this press
release. We undertake no obligations to update or revise publicly
any forward-looking statements, whether as a result of new
information, future events or otherwise other than as required
under the federal securities laws.
Global Media Contact
Heather Stamatacos
Vice President, Business Communications
Avantor
484-846-3643
heather.stamatacos@avantorsciences.com
Investor Relations Contact
Christina Jones
Vice President, Investor Relations
Avantor
805-617-5297
Christina.Jones@avantorsciences.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/avantor-announces-ger-brophy-to-retire-in-2024-benoit-gourdier-appointed-evp-biopharma-production-301938210.html
SOURCE Avantor and Financial News